Browse Health
Oncology Specialist (cancer)


Education ?

Medical School Score Rankings
University of Colorado
Top 25%

Affiliations ?

Dr. Maltzman is affiliated with 1 hospitals.

Hospital Affiliations

  • Philadelphia Veterans Affairs Medical Center
    3900 Woodland Ave, Philadelphia, PA 19104
  • Publications & Research

    Dr. Maltzman has contributed to 9 publications.
    Title Human Epidermal Growth Factor Receptor 2 (her2) Extracellular Domain Levels Are Associated with Progression-free Survival in Patients with Her2-positive Metastatic Breast Cancer Receiving Lapatinib Monotherapy.
    Date December 2011
    Journal Cancer

    Changes in serum human epidermal growth factor receptor 2 (HER2) levels associated with clinical outcomes, including objective response rate, progression-free survival (PFS), and overall survival have been reported in patients with metastatic breast cancer (MBC) receiving trastuzumab and chemotherapy. This study investigated whether baseline or changes in serum HER2 correlated with overall response rate (ORR) and/or PFS in patients with MBC receiving first-line lapatinib monotherapy.

    Title Quality of Life in Hormone Receptor-positive Her-2+ Metastatic Breast Cancer Patients During Treatment with Letrozole Alone or in Combination with Lapatinib.
    Date January 2011
    Journal The Oncologist

    A phase III trial compared lapatinib plus letrozole (L + Let) with letrozole plus placebo (Let) as first-line therapy for hormone receptor (HR)(+) metastatic breast cancer (MBC) patients. The primary endpoint of progression-free survival (PFS) in patients whose tumors were human epidermal growth factor receptor (HER)-2(+) was significantly longer for L + Let than for Let (8.2 months versus 3 months; p = .019). This analysis focuses on quality of life (QOL) in the HER-2(+) population.

    Title Lapatinib Plus Letrozole As First-line Therapy for Her-2+ Hormone Receptor-positive Metastatic Breast Cancer.
    Date June 2010
    Journal The Oncologist

    To evaluate the efficacy and tolerability of letrozole plus lapatinib versus letrozole plus placebo in women with hormone receptor (HR)(+) human epidermal growth factor receptor (HER)-2(+) tumors receiving first-line therapy for metastatic breast cancer (MBC).

    Title Lapatinib Combined with Letrozole Versus Letrozole and Placebo As First-line Therapy for Postmenopausal Hormone Receptor-positive Metastatic Breast Cancer.
    Date January 2010
    Journal Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology

    Cross-talk between human epidermal growth factor receptors and hormone receptor pathways may cause endocrine resistance in breast cancer. This trial evaluated the effect of adding lapatinib, a dual tyrosine kinase inhibitor blocking epidermal growth factor receptor and human epidermal growth factor receptor 2 (HER2), to the aromatase inhibitor letrozole as first-line treatment of hormone receptor (HR) -positive metastatic breast cancer (MBC).

    Title Autocrine Expression and Ontogenetic Functions of the Pacap Ligand/receptor System During Sympathetic Development.
    Date April 2000
    Journal Developmental Biology

    The superior cervical ganglion (SCG) is a well-characterized model of neural development, in which several regulatory signals have been identified. Vasoactive intestinal peptide (VIP) has been found to regulate diverse ontogenetic processes in sympathetics, though functional requirements for high peptide concentrations suggest that other ligands are involved. We now describe expression and functions of pituitary adenylate cyclase-activating polypeptide (PACAP) during SCG ontogeny, suggesting that the peptide plays critical roles in neurogenesis. PACAP and PACAP receptor (PAC(1)) mRNA's were detected at embryonic days 14.5 (E14.5) through E17.5 in vivo and virtually all precursors exhibited ligand and receptor, indicating that the system is expressed as neuroblasts proliferate. Exposure of cultured precursors to PACAP peptides, containing 27 or 38 residues, increased mitogenic activity 4-fold. Significantly, PACAP was 1000-fold more potent than VIP and a highly potent and selective antagonist entirely blocked effects of micromolar VIP, consistent with both peptides acting via PAC(1) receptors. Moreover, PACAP potently enhanced precursor survival more than 2-fold, suggesting that previously defined VIP effects were mediated via PAC(1) receptors and that PACAP is the more significant developmental signal. In addition to neurogenesis, PACAP promoted neuronal differentiation, increasing neurite outgrowth 4-fold and enhancing expression of neurotrophin receptors trkC and trkA. Since PACAP potently activated cAMP and PI pathways and increased intracellular Ca(2+), the peptide may interact with other developmental signals. PACAP stimulation of precursor mitosis, survival, and trk receptor expression suggests that the signaling system plays a critical autocrine role during sympathetic neurogenesis.

    Title A Questionnaire Study of 138 Patients with Restless Legs Syndrome: the 'night-walkers' Survey.
    Date February 1996
    Journal Neurology

    After verifying the diagnosis of restless legs syndrome (RLS) in 105 patients who are part of a nationwide support group, we undertook a telephone survey of their symptomatology. We then compared the answers with those of 33 of our own RLS patients who had undergone a neurologic examination and had a periodic limb movement in sleep (PLMS) index of > 5 (number per hours of sleep). Although RLS has generally been considered to be a condition of middle to older age, the results for the support group, and for our patients, are similar in that more than a third of the patients in each group experienced their first symptoms before the age of 10. Initial lack of diagnosis or misdiagnosis by a physician were common and the symptoms were commonly thought to be psychogenic whatever the age of onset. In some cases, young age-onset RLS was severe from the start. For younger age-onset patients whose symptoms were severe enough to seek immediate medical attention, confounding or misdiagnosis included "growing pains" and attention deficit hyperactivity disorder. However, medical attention was generally not sought until the fourth decade. Most respondents stated that this was because their symptoms were mild at onset and then progressed. In the older age-onset patients, misdiagnoses also included skin irritation, arthritis, and malingering. A total remission of symptoms of a month or more was present in at least 15% of the individuals in all groups surveyed. More than 50% of the respondents know of one or more first-degree relatives affected by RLS. Five of our 33 patients had RLS initially triggered either by diabetic peripheral neuropathy or lumbosacral radiculopathy.

    Title Molecular Evidence for the Expression of Nicotinic Acetylcholine Receptor Alpha-chain in Mouse Thymus.
    Date June 1992
    Journal Journal of Immunology (baltimore, Md. : 1950)

    The presence and structure of nicotinic acetylcholine receptor (nAChR) in the thymus has been a subject of interest for many years because of its possible role in the pathogenesis of the autoimmune disease myasthenia gravis. Using the polymerase chain reaction with primers specific for the alpha-chain of nAChR (nAChR-alpha), an 880-bp homologous band was found after amplification of cDNA prepared from mouse thymus, thymic medullary and cortical epithelial cell lines, but not from thymocytes or kidney. Sequencing of the polymerase chain reaction product from the thymus and thymic medullary and cortical epithelial lines showed identity with skeletal muscle nAChR-alpha over the region examined. This region includes the domains of the molecule on which B cell and T cell autoantigenic targets have been described. No evidence was found in mouse tissue for the exon 3A, which has been described in human muscle and the human rhabdomyosarcoma cell line TE671. Our results provide evidence at the RNA level for the expression of the nAChR-alpha on stromal cells but not on thymocytes in normal murine thymus and are consistent with a role for intrathymic autoantigen expression in the pathogenesis of myasthenia gravis.

    Title Expression of the V Beta 5.1 Gene by Murine Peripheral T Cells is Controlled by Mhc Genes and Skewed to the Cd8+ Subset.
    Date February 1990
    Journal Journal of Immunology (baltimore, Md. : 1950)

    We have examined the usage of the V beta 5.1 region in peripheral T cell populations of several mouse strains by measuring V beta 5.1 transcript levels. The results show that V beta 5.1 is expressed predominantly by CD8+ T cells in mice of several MHC haplotypes. This finding suggests that V beta 5.1 may confer restriction to class 1 molecules present in these strains. Interestingly, however, T cells expressing V beta 5.1, like those expressing V beta 17a and V beta 11, are clonally deleted from both CD4 and CD8 subsets in mice that express MHC IE molecules. The latter result implies that V beta 5.1 confers reactivity to a class 2 molecule (IE). These results are discussed in terms of positive selection and clonal deletion. Finally we provide evidence that genes in the K or A regions of the MHC also control V beta 5.1 usage.

    Title Positive Selection Determines T Cell Receptor V Beta 14 Gene Usage by Cd8+ T Cells.
    Date August 1989
    Journal The Journal of Experimental Medicine

    We report here a mAb, 14-2, reactive with TCRs that include V beta 14. The frequency of V beta 14+ T cells varies with CD4 and CD8 subset and is controlled by the H-2 genes. Thus CD8+ T cells from H-2b mice include approximately 2.3% V beta 14+ T cells while CD8+ T cells from mice expressing K kappa include greater than 8% V beta 14+ T cells. In all strains examined, 7-8% of CD4+ T cells express V beta 14. The frequent usage of V beta 14 in CD8+ T cells of K kappa-expressing mice is a result of preferential positive selection of V beta 14+ CD8+ T cells as demonstrated by analysis of radiation chimeras. These studies demonstrate that H-2-dependent positive selection occurs in unmanipulated mice. Furthermore, the results imply that positive selection, and possibly H-2 restriction, can be strongly influenced by a V beta domain, with some independence from the beta-junctional sequence and alpha chain.

    Similar doctors nearby

    Dr. Lee Schacter

    Internal Medicine
    39 years experience
    Philadelphia, PA

    Dr. Charlotte Gauwerky

    Internal Medicine
    40 years experience
    Philadelphia, PA

    Dr. Stephen Hahn

    Radiation Oncology
    28 years experience
    Philadelphia, PA

    Dr. Tal Zaks

    Hematology & Oncology
    16 years experience
    Philadelphia, PA

    Dr. Frank Balis

    37 years experience
    Philadelphia, PA

    Dr. Stella Chou

    12 years experience
    Philadelphia, PA
    Search All Similar Doctors